Fair-Value Report — Elife Holdings Ltd (0223.HK)

Insider Signal

Context: In April 2026 Elife completed a placing of 271,220,000 new shares at HK$0.102 (raising ~HK$27.1M net). On 6 May 2026, 85.5M share options (exercise price HK$0.131) and 9.3M share awards were granted to employees. Liu Qiuhua's purchase at ~HK$0.11 post-dates both events and is distinct from them.

Verified Snapshot

Book value derivation (best estimate, ~May 2026): H1 FY2026 interim equity (30 Sep 2025): HK$52.97M + placing net proceeds HK$27.1M = ~HK$80.1M ÷ 1,627.4M shares = HK$0.049/share. This is an estimate — FY2026 annual results (year ended 31 Mar 2026) have not yet been released as of the research date. If H2 FY2026 continued to lose money materially, BV/share would be lower. No audited post-placing book value is available; treat estimate with caution.

Business Description

Elife Holdings Limited (易生活控股有限公司) is a Hong Kong–incorporated investment holding company that operates in three segments: (1) Supply Chain Business — procurement/distribution of branded consumer goods in HK and mainland China; (2) Daily Cleaning, Anti-Epidemic & Other Consumable Products; and (3) Licensed Branded Consumer Goods. The company was founded in 1991 and listed on the Main Board of HKEX.

In April 2026, management announced a strategic pivot toward an "AI-driven digital supply chain ecosystem" and entered a strategic partnership with Shanghai Your Supply Chain Management. Board was substantially refreshed in March 2025 (Zhao Zhenzhong became Vice Chairman / Acting Chairman). The new board also adopted a new share scheme in March 2026 and completed a HK$27.1M equity placing in April 2026. These are early-stage transformation signals; no financial results under the new strategy have been reported yet.

In March 2026, the company disclosed the disposal of an entire equity interest in one subsidiary for RMB820,000 — a minor asset shed, but suggestive of ongoing restructuring rather than growth.

Valuation

Method: Asset-based (P/B) + Scenario Analysis

A profitable-company DCF is not applicable: Elife has generated net losses in every one of the past five fiscal years, with no credible near-term earnings forecast available (zero analyst coverage). The appropriate method for this stage is book-value anchoring with scenario multiples reflecting the probability of a successful strategic pivot, supplemented by a reverse read.

Anchor: Post-placing estimated BV/share ≈ HK$0.049 (H1 FY2026 equity HK$52.97M + placing proceeds HK$27.1M, divided by 1,627.4M shares; FY2026 full-year results not yet available).

Reverse Read

At HK$0.112, the market prices in P/B of ~2.3×. For this to be justified on a normalised basis, the company would need to earn a sustainable ROE of roughly 12–15% on post-placing equity (~HK$80M), implying net profit of ~HK$10–12M per year. Against a backdrop of five consecutive loss years (cumulative ~HK$219M in net losses FY2021–FY2025, including FY2025's HK$97.84M loss), this is a heroic assumption with zero demonstrated evidence.

Peer Comparison

Comparable HK-listed small/micro-cap consumer distribution and supply chain companies; data sourced from public filings and financial data providers as of May/June 2026. Note: micro-cap data quality is limited; treat as indicative only.

Elife's P/B of ~2.3× sits above even the profitable peer median, despite zero profitability over five years. A credible turnaround would still justify only ~1.0–1.5× book.

Conclusion

Rating: SPECULATIVE SELL

The insider signal is genuine — Liu Qiuhua has made a meaningful open-market purchase (~HK$7.5M), doubling their stake to 8.26%. This represents real capital at risk and is not a placing artifact or scheme award. It deserves attention.

However, the signal tells us about buyer conviction, not fundamental value. Elife at HK$0.112 prices in a successful strategic transformation that has not been demonstrated. The company's five-year loss record is severe, FY2025 dramatically worsened, revenue has been declining, and the "AI supply chain" pivot was announced in April 2026 with no financial results yet. The buyer's motive is entirely opaque — Liu Qiuhua is not a director or publicly identified strategic partner.

Our base-case fair value is HK$0.039 and bull-case is HK$0.074. At HK$0.112, the stock is priced for perfection on a thesis that does not yet exist. The stock is also near its 52-week low (HK$0.11), having fallen ~61% from its 52-week high of HK$0.285, suggesting earlier momentum has fully unwound.

We rate Elife Holdings Speculative Sell with a base-case fair value of HK$0.04. Investors who wish to speculate on the pivot story should size positions to reflect the high probability of continued losses and further dilution. Signal real; price wrong.

Key Risks

• Continued losses and cash burn: Five consecutive net loss years; FY2025 loss HK$97.84M (worst ever). FY2026 results not yet released. Cash runway estimated at ~18–24 months post-placing but depends on burn rate.
• Further dilution: 85.5M share options (exercise price HK$0.131) and 9.3M share awards granted May 2026; 20% general issue mandate held by the board. Repeated placings have diluted existing holders ~20% in early 2026 alone.
• Unproven pivot: The "AI-driven digital supply chain" strategy was announced April 2026 with no financial evidence of traction. Strategic partnerships at early-concept stage carry execution risk.
• Revenue decline: Revenue has fallen from HK$276M (FY2021) to HK$178M (FY2025) — a 35% decline over four years. The core business is shrinking.
• Board instability: New board appointed March 2025; multiple governance changes in 2025–2026. High leadership turnover increases uncertainty.
• Delayed financial reporting: FY2026 annual results (year ended 31 March 2026) have not been released as of June 3, 2026 — flag noted. Post-placing book value is estimated, not audited.
• Liquidity and micro-cap risk: Market cap HK$185M, no analyst coverage, wide spreads typical for this price range. Entry/exit costs are high relative to position size.
• Opaque insider motive: Liu Qiuhua's background, industry connection, and investment rationale are unknown. Cannot distinguish between a truly informed buyer and a momentum trader.

Sources

• HKEX DI filing, screen_signals.py output — Liu Qiuhua 26 May 2026 (reason 1101/1103)
• Elife Holdings — Grant of Share Options and Share Awards announcement, 6 May 2026 (HKEX)
• Elife Holdings — Placing of New Shares Under Specific Mandate / EGM Circular, 6 February 2026 (HKEX)
• Elife Holdings — AGM Circular (re-election, share scheme, mandates), 9 January 2026 (HKEX) — source of 1,356,171,754 share count
• StockAnalysis.com — financials, balance sheet, share price HK$0.112 (3 Jun 2026)
• Simply Wall St — financial health data (2 Jun 2026)
• Investing.com / Yahoo Finance — general company profile
• TipRanks — placing completion announcement summary (HK$27.1M net proceeds, Apr 29 2026)